Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ASTH vs LTBR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ASTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)
ASTH Overall Winner
6-Pillar Tally: ASTH 6 – 0 LTBR
Matrix Metrics: ASTH 10 – 0 LTBR
As of Nov 16, 2026, Astrana Health Inc. (ASTH) is the stronger overall head-to-head candidate over Lightbridge Corp. (LTBR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ASTH carries a Unified Composite Score of 53.2/100 (HOLD) at $32.94 (9.1x Forward P/E, 2.6% operating margin), whereas LTBR carries 40.4/100 (SELL) at $3.84 (N/M Forward P/E, 0.0% operating margin).
- Technical & Structure Timing Caution: ASTH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.8); meanwhile LTBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ASTH vs LTBR
ASTH
Head-to-Head Winner
Astrana Health Inc. Common Stock
$32.94
+3.58% 1D
Market Cap
$1.6B
TTM Revenue
$3.91B
Forward P/E
9.1x
Beta / 30D Vol
0.40β · 60% Vol
Unified Composite Score
53.2
HOLD
Tech 59.0
Fund 56.0
Flow 59.0
Mom 56.0
Weinstein Technical Phase
Markdown · Sell / avoid
LTBR
Lightbridge Corp.
$3.84
-6.34% 1D
Market Cap
$164.7M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
3.45β · 98% Vol
Unified Composite Score
40.4
SELL
Tech 33.0
Fund 50.0
Flow 56.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ASTH 6 – 0 LTBR)
1. Valuation Multiples
ASTH
Forward P/E
9.1x
N/M
Trailing P/E
30.6x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.6x
N/M
2. Growth & Scale
ASTH
Revenue Growth (YoY)
+7.1%
+0.0%
Earnings Growth (YoY)
N/A
+0.0%
TTM Revenue (USD)
$3.91B
N/A
Market Cap
$1.6B
$164.7M
3. Profitability & Quality
ASTH
Gross Margin
11.0%
N/A
Operating Margin
2.6%
0.0%
Net Profit Margin
1.4%
0.0%
Return on Equity (ROE)
9.8%
-14.1%
4. Balance Sheet & Cash Flow
ASTH
Cash Generation (TTM)
$99M
-$19M
Cash Flow Margin
2.5%
N/A
Net Cash / Leverage
$581M Net Debt (1.14x D/E)
$6.61 Book/Sh · -14.1% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ASTH
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
56.4% (11th %ile)
79.6% (32nd %ile)
Put/Call OI Skew
N/A
5.63x (Put-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
ASTH
OpEx & R&D Intensity
8.4% of Rev ($329M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Care Facilities Operator
Electrical Equipment & Parts Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ASTH (10) vs LTBR (0)| Institutional Metric | ASTH | LTBR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.6B | $164.7M | ASTH | |
| Trailing P/E Ratio | 30.6x | N/M | ASTH | |
| Forward P/E Ratio | 9.1x | N/M | ASTH | |
| Revenue Growth (YoY) | +7.1% | +0.0% | ASTH | |
| Operating Margin (TTM) | 2.6% | 0.0% | ASTH | |
| Net Profit Margin | 1.4% | 0.0% | ASTH | |
| Return on Equity (ROE) | 9.8% | -14.1% | ASTH | |
| 52-Week Range Position | 44% ($18–$52) | 0% ($4–$20) | ASTH | |
| Beta / 30D Volatility | 0.40β · 60% Vol | 3.45β · 98% Vol | ASTH | |
| Unified Institutional Score | 53.2 / 100 (HOLD) | 40.4 / 100 (SELL) | ASTH | |
| Trailing 12M Revenue (USD) | $3.91B | N/A | Scale | |
| Gross Profit Margin (TTM) | 11.0% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.6x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $99M ($581M Net Debt (1.14x D/E)) | -$19M ($6.61 Book/Sh · -14.1% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ASTH +15.79 pp
3M Horizon
ASTH +36.0 pp
6M Horizon
ASTH +49.11 pp
1Y Horizon
ASTH +128.96 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ASTH Revenue | LTBR Revenue | ASTH Op. Margin | LTBR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $520M | N/A | 17.0% | N/A | ASTH |
| FY2019 | $560M | N/A | 5.8% | N/A | ASTH |
| FY2020 | $690M | N/A | 11.7% | N/A | ASTH |
| FY2021 | $770M | N/A | 12.7% | N/A | ASTH |
| FY2022 | $1.14B | N/A | 9.1% | N/A | ASTH |
| FY2023 | $1.39B | N/A | 6.1% | N/A | ASTH |
| FY2024 | $2.03B | N/A | 4.4% | N/A | ASTH |
| FY2025 | $3.18B | N/A | 2.5% | N/A | ASTH |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ASTH
BREAKDOWN
Current IV
56.4%
IV Percentile
11th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact ASTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
LTBR
BREAKDOWN
Current IV
79.6%
IV Percentile
32nd %ile
Put/Call OI Skew
5.63x (Put-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact LTBR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ASTH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
OpEx & R&D Reinvestment
8.4% of Rev ($329M)
90D Engineering Disclosures
0 Published
LTBR Moat Profile
Cyclical / Execution-Driven Positioning
Electrical Equipment & Parts Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ASTH vs LTBR Key Questions & Quantitative Answers
As of Nov 16, 2026, Astrana Health Inc. (ASTH) is the stronger overall head-to-head candidate over Lightbridge Corp. (LTBR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ASTH carries a Unified Composite Score of 53.2/100 (HOLD) at $32.94 (9.1x Forward P/E, 2.6% operating margin), whereas LTBR carries 40.4/100 (SELL) at $3.84 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ASTH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.8); meanwhile LTBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ASTH leads the Growth & Scale pillar: ASTH posts +7.1% YoY revenue growth and N/A YoY earnings growth on $3.91B TTM revenue (11.0% gross margin, 2.6% operating margin), compared with LTBR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ASTH cumulative revenue shifted +511.5% while LTBR shifted N/A. In operating R&D and SG&A reinvestment, ASTH deploys 8.4% of Rev ($329M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LTBR.
ASTH screens cheaper on headline valuation multiples. ASTH trades at 9.1x Forward P/E, 30.6x Trailing P/E, N/M PEG, and 0.6x EV/Revenue (2.5% FCF margin), whereas LTBR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ASTH (9.8% ROE) versus LTBR (-14.1% ROE) capital efficiency.
In options market volatility and institutional positioning, ASTH carries 56.4% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.40β · 60% Vol realized risk). By comparison, LTBR carries 79.6% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 5.63x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.45β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
LTBR vs ASTH · Reverse Pair
ASTH vs ARDT
· Sector Peer
ASTH vs BWIN
· Sector Peer
ASTH vs PRVA
· Sector Peer
LTBR vs LEU
· Sector Peer
LTBR vs NNE
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem